中文版
 
R&D PORTFOLIO
/ OB-318

6场半全场11087:OB-318

6场半全场有多少奖金 www.dkpgas.com.cn

Indication
New Anti-cancer Drug
Mechanism
Mechanism of Action: Composite mechanism of action effectively inhibit the growth, metastasis, and angiogenesis of tumor.
Status
USFDA and TFDA approved phase I clinical trials.
Product Advantages
1.Efficacy: significantly inhibit the growth of tumor in allogenic subcutaneous xenograft model or refractory orthotopic xenograft model of maliligant cancers.
2.Safety: The concentration ration that inhibit cancer cells and normal cells reaches 100 times, with optimal selectively.
3.Quality: standard quality control procedures to effectively control active ingredients from the fermentation of raw materials to final products.
4.Exclusiveness: Antrodia cinnamomea is an endemic species of Taiwan, with related research and development leading the world. Foreign competitors can hardly have access to the raw materials.
Potential Market
The market for anti-liver cancer drugs was about 24.5 billion US dollars in 2014. It is expected to grow to 33.8 billion US dollars in 2019.
  • The OB318 is according the ICH guideline and USFDA published standards to execut the pre-clinical research. All the technologies and quality are followed the international standards. Multiple cancer cell lines and normal cell line were used to evaluate the anticancer activity and safety range. The anticancer activity of OB318 was also verified by different animal models of diseases.